600721 百花医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.1481.889-5.1579.200-40.630
总资产报酬率 ROA (%)2.0841.257-3.5056.114-28.224
投入资产回报率 ROIC (%)2.5561.551-4.2877.646-35.761

边际利润分析
销售毛利率 (%)47.75249.03739.91840.039-161.954
营业利润率 (%)12.6734.862-8.78622.584-438.647
息税前利润/营业总收入 (%)12.3084.229-9.25822.061-353.334
净利润/营业总收入 (%)11.5443.513-9.92821.281-378.283

收益指标分析
经营活动净收益/利润总额(%)157.070413.100-82.17354.05573.178
价值变动净收益/利润总额(%)7.03511.860-0.0340.707-2.330
营业外收支净额/利润总额(%)-0.317-8.9464.282-2.197-17.458

偿债能力分析
流动比率 (X)1.8101.8311.7491.8441.429
速动比率 (X)1.4291.4261.2321.0790.818
资产负债率 (%)34.10933.46433.41030.13935.962
带息债务/全部投入资本 (%)14.30812.72811.98410.95512.088
股东权益/带息债务 (%)562.977642.967687.595765.453680.754
股东权益/负债合计 (%)193.175198.825199.308230.123176.670
利息保障倍数 (X)-37.907-18.028117.429-581.341-17.565

营运能力分析
应收账款周转天数 (天)22.99617.45119.09225.494547.610
存货周转天数 (天)220.867262.317294.099408.022345.723